Clinical trial
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
NCT06771115 is registered in ClinicalTrials.gov with Zomagen Biosciences Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
- Lead sponsor
- Zomagen Biosciences Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 7, 2025
- Completion date
- September 10, 2025
- Enrollment
- 175 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.